AstraZeneca PLC
AstraZeneca's Climate Target Data Preview
As of 2024, AstraZeneca has disclosed 8 climate targets aimed at reducing its greenhouse gas (GHG) emissions. These include 8 absolute reduction targets, signaling the company’s commitment to managing and lowering its carbon footprint over time. The targets span various emissions scopes and time horizons, offering insight into AstraZeneca ’s climate strategy, ambition level, and alignment with global decarbonization goals.
| Target Type | Scope of Target | Unit | Target | Target Year |
|---|---|---|---|---|
Absolute-based Target | Scope 1 - Total, Scope 2 - Total | Metric Tonnes of CO2 equivalent (mtCO2e) | Copy restricted. Please purchase to unlock this data.  | 2026 |
Absolute-based Target | Scope 3 - Upstream Transportation and Distribution (Cat. 4), Scope 3 - Business Travel (Cat. 6) | Metric Tonnes of CO2 equivalent (mtCO2e) | Copy restricted. Please purchase to unlock this data.  | 2030 |
Absolute-based Target | Scope 3 - Fuel- and Energy-Related Services (Cat. 3), Scope 3 - Upstream Leased Assets (Cat. 8) | Metric Tonnes of CO2 equivalent (mtCO2e) | Copy restricted. Please purchase to unlock this data.  | 2030 |
Absolute-based Target | Scope 3 - End-of-Life Treatment of Sold Products (Cat. 12) | Metric Tonnes of CO2 equivalent (mtCO2e) | Copy restricted. Please purchase to unlock this data. | 2030 |
Absolute-based Target | Scope 3 - Total Upstream (Cat. 1+2+3+4+5+6+7+8), Scope 3 - Downstream Transportation and Distribution (Cat. 9), Scope 3 - Use of Sold Products (Cat. 11), Scope 3 - End-of-Life Treatment of Sold Products (Cat. 12), Scope 3 - Downstream Leased Assets (Cat. 13) | Metric Tonnes of CO2 equivalent (mtCO2e) | Copy restricted. Please purchase to unlock this data.  | 2030 |
Absolute-based Target | Scope 3 - Purchased Goods and Services (Cat. 1) | Metric Tonnes of CO2 equivalent (mtCO2e) | Copy restricted. Please purchase to unlock this data. | 2030 |
Absolute-based Target | Scope 3 - Use of Sold Products (Cat. 11) | Metric Tonnes of CO2 equivalent (mtCO2e) | Copy restricted. Please purchase to unlock this data.  | 2030 |
Absolute-based Target | Scope 3 - Total Upstream (Cat. 1+2+3+4+5+6+7+8), Scope 3 - Downstream Transportation and Distribution (Cat. 9), Scope 3 - Use of Sold Products (Cat. 11), Scope 3 - End-of-Life Treatment of Sold Products (Cat. 12), Scope 3 - Downstream Leased Assets (Cat. 13) | Metric Tonnes of CO2 equivalent (mtCO2e) | Copy restricted. Please purchase to unlock this data.  | 2045 |
This table provides a simplified preview of selected climate targets data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
Insights into AstraZeneca's Greenhouse Gas Emissions Pathways
As of 2024, AstraZeneca has set greenhouse gas (GHG) emissions reduction targets that cover both its operational emissions (Scope 1 and 2) and value chain emissions (Scope 3), offering a comprehensive view of its total carbon footprint.
Does AstraZeneca have a target to reduce the emissions from its operations?
As of 2024, AstraZeneca has set a target to reduce its operational greenhouse gas (GHG) emissions, specifically those from Scope 1 and Scope 2 sources.
AstraZeneca's most ambitious operational target is to reduce these emissions by 98% by 2026, compared to a baseline of 620,818 Metric Tonnes of CO2 equivalent (mtCO2e) in 2015.
As of 2024, AstraZeneca is lagging behind on its operational emissions reduction target, having achieved 79.09% of the planned reduction.
AstraZeneca's Operational (Scope 1+2) Emissions Pathway
Does AstraZeneca have a target to reduce the emissions from its value chain?
As of 2024, AstraZeneca has set a target to reduce its value chain greenhouse gas (GHG) emissions, covering 1 out of the 15 Scope 3 categories defined by the GHG Protocol.
AstraZeneca's most ambitious value chain target is to reduce these emissions by 95% by 2030, compared to a baseline of 1,037,501 Metric Tonnes of CO2 equivalent (mtCO2e) in 2019.
Instead of reducing value chain emissions, AstraZeneca has increased them, with 2024 levels exceeding those of the 2019 baseline, placing the company well behind its reduction target.